What is the average MRD lead time across subtypes?

What is the average MRD lead time across subtypes?

• A. About 3 months
• B. About 24 months
• C. About 6 months
• D. About 12 months

Answer: (D)

Minimal residual disease (MRD) refers to the tiny number of cancer cells that remain after treatment and can be detected with sensitive assays. The MRD lead time is the interval from starting therapy to when MRD status becomes detectable or shows a change during monitoring. Across subtypes, treatment courses typically span roughly a year, with MRD assessments often performed after induction and consolidation phases. This makes about 12 months the common, average lead time across subtypes. While individual cases vary, a year captures the central tendency for when MRD changes are most often observed in diverse subtypes.

Minimal residual disease (MRD) refers to the tiny number of cancer cells that remain after treatment and can be detected with sensitive assays. The MRD lead time is the interval from starting therapy to when MRD status becomes detectable or shows a change during monitoring. Across subtypes, treatment courses typically span roughly a year, with MRD assessments often performed after induction and consolidation phases. This makes about 12 months the common, average lead time across subtypes. While individual cases vary, a year captures the central tendency for when MRD changes are most often observed in diverse subtypes.